REMINDER: Our user survey closes on Friday, please submit your responses here.
Eisai Interview Video
https://x.com/RedditDeluxe/status/1744387263851630893?s=20
Hi Sangi,
Apologies, yes he starts the description of Eisai with "huge" and then finishes with "large". ( Perhaps trying to show some uncharacteristic restraint! lol) See attached video clip posted on Twitter.
I have called out TwoGood and you're correct, for evenhandedness, I should have also called out the moronic ramping posts too. I have been on LSE for a few years now and there are a few posters whose agendas/actions seen more insidious than others. But yes, Idle ramping or deramping with little or no factual gravity, or just downright misinformation, is the bane of these boards.
Sangi,
Yeah, I think when Newland was referring to huge pharma companies he wasn't putting Eisai in that bracket, I say this as in last week's Proactive Interview he refers to Eisai as "large". So hopefully the huge ones are still set to land?
I have looked at the Nanotech competitor options and they seem a little way off in terms of readiness to market and gain FDA/CE mark approval. (So at the very least AGL should have a decent amount of time to monopolise the market)
Well that was a waste of my time and effort Sangi.
That's your opinion re "staying afloat". Mine differs from that as I have been very impressed with the work done over the past year to make the tech more commercially viable and accessible. Cash burn will be significantly lower this/next year and with the recent developments I am expecting a steady flow of new contracts. (probably following the Eisai route of PILOT STUDY expanding into further fields of commercial interest in the target company.)
I bought in with a significant stake at the beginning of December at around 11p and have been encouraged by the progress so far. I'll be holding for a share price closer to that of Berenberg's at £1.20p, it may take time but I am patient.
Hi Sangijuelas1
Here is the breakdown from the 9th November "Trading and Business Update" RNS:
"The Company expects revenue recognised for 2023 will be c. £2.2 million, which is an increase of 120% over revenue achieved in 2022 but below current market consensus of c. £3.0 million. New sales secured in 2023 are expected to be c. £3.3 million however revenue recognition for some of these sales will fall into the 2024 financial year. Gross margin for H2 is expected to be higher than H1 reflecting the product-service mix and, together with tight cost control, to result in the cash position at 2023 year end being in line with consensus at c. £15 million.
Revenue recognised for 2024 is expected to treble compared to 2023 with the growth of distributor sales, and with the planned launches of the Portrait PD-L1 test (services), see separate announcement today, the Portrait+ antibody staining kit (products), and the Parsortix BiDetectTM DNA solutions combining ctDNA and CTC-DNA analysis (products and services) all contributing to the Company's sales growth ambitions.
Here's a useful factual summary thread for new/prospective investors:
Parsortix CTC Timor cell harvesting device has:
- US FDA Approval
- EU CE Mark
- UK UKCA Mark
- 26 granted patents inc USA, China, Europe, Japan, Canada & Australia until 2034
- Rights to market in USA, UK & Europe currently
- Portrait+ Kit launched last month at San Antonio Breast Cancer Symposium.
Financials:
- Debt Free
- Cash in the bank of £15m = over 50% of current MCAP
- Fully funded cash runway until Q2 2025
- 2023 Revenue up 120%
- 2024 Revenue expected to treble (not including any new deals)
- Cost streamlining in place
- Directors have skin in the game & bought most recently at 28p to 29.75p (prior to this at 80p)
- Staff share options exercisable at 25.75p
Upcoming Catalysts:
- Assay updates
- Molecular study results
- Major pharmaceutical deals (as per recent webinar)
- Due to the diverse service offering, the CEO has stated: “a single deal could be worth 100’s of millions”
Conclusion:
- Lack of commercial deals has been the main criticism over the years. However, AGL has been working to simplify the service offering for easier commercialisation (new Portrait+ kit & molecular studies etc) Are AGL at a turning point?
It would appear that the strong start to 2024 is an indicator all is moving along very well, with the Pilot study contract with the large multibillion-dollar Eisai pharmaceutical company based in Japan and last week's excellent "Better than anticipated" study results. The findings from the study are of particular significance for AGL as it includes mutations that are targeted by FDA-approved *cancer drugs, yet were missed by traditional ctDNA analysis. These *Drugs are marketed by pharma majors Astra Zeneca, Roche, Novartis et al.
https://x.com/RedditDeluxe/status/1743630260497772868?s=20
https://x.com/RedditDeluxe/status/1735222212985082111?s=20
Well despite differences of opinion, it’s been a very positive start to 2024 for AGL.
Have a great weekend all.
Bantham,
There will always be those who buy on a high and, if they’re short term day traders, will be left selling at a loss. I’m more focussed on investors with more than a few days patience in them. If they, as I, have invested in a company they’ve researched, done due diligence on and believe to have big potential, then as long as they are patient enough to let the company develop, then buying at any level today will see them do very well.
But as I said earlier, let’s let this play out over the coming weeks and see where we stand then.
Well, this board takes the biscuit. As an investor who has a near TR1 share holding who bought in at 11p recently, all I can say is that we will just have to see where the company and share price stand in the coming weeks and months.
If the company haven’t started to monetise Parsortix effectively and the funds (due to last until Q2 2025 as per recent RNS) dry up, then I’ll happily hold my hands up and say I’ve invested my money badly.
However if this is a turnaround for AGL and the work they’ve done recently to make commercialisation more accessible/desirable (the reason I’ve bought in) then a few on this board should really take a long hard look in the mirror and consider whether their posts on here have encouraged potential investors to stay clear and miss this opportunity in making money and supporting a cancer research focussed company.
I can’t stand idle ramping, but agenda driven deramping/shorting (particularly of a cancer related stock) is a morally bankrupt endeavour l… naming no names TwoGood et al.
It’s been a great start to 2024… Long may it continue for investors new/longterm and for benefit cancer patients out there.
TwoGood2Die??? Please elaborate. We already have FDA approval, CE mark, UK mark, 26 patents, approved sales platforms in USA, China, UK, Europe, Japan and Australasia and the list goes on.
You state the RNS’d success percentages aren’t good enough for diagnostic purposes when you know (and criticised/posted last week) that this tech isn’t used in direct patient diagnostics and is designed and marketed for the cancer research market.
WARNING TO ALL NEW INVESTORS: DO YOUR OWN RESEARCH AND BE WARY OF AGENDA DRIVEN POSTERS LIKE THIS GUY.
START WITH THIS LINK:
https://x.com/redditdeluxe/status/1735222212985082111?s=46&t=IHEn1TE0c7FNFBktt6H8XQ
As you’ll see if you look back over the past few weeks of posts on this board, there has been a concerted effort by TwoGood2Die to deramp this share.
He/She wouldn’t answer whether they were a current or former holder of AGL and their posts were poorly researched and lacking any credibility.
There’s usually a few options for this type of action: they’re shorting the company, or they’ve lost money here before and hold a grudge, or they are trying to drive the price down for a lower entry. (Or of course a more insidious agenda)
TwoGood2Die Certainly should be ashamed of himself. Mindless deramping with barely an whiff of sense/research/wit.
I wonder how many newbie investors he/she put off buying and subsequently missed this recent rise and overall opportunity.
Really rather shameful to be deramping/shorting a company specialising in cancer research. Report, block and move on.
"An impressive start to 2024 for #AGL
Here CEO Andrew Newland highlights the revenue potential from yesterday's pilot study announcement with multibillion-dollar pharmaceutical company Eisai
As previously stated: "A single contract could generate tens of millions in revenue"
https://x.com/RedditDeluxe/status/1742922848036090236?s=20
Interesting addition at the end of the RNS:
“ ANGLE is engaging with Illumina, leading KOLs and oncologists to seek their input and consideration of the benefits of the combined ctDNA / CTC-DNA approach giving a new and unique insight into cancer clonal evolution. The early stage responses have been encouraging.”
Bantham, yeah we can only wait and see where this will end up. In my opinion this news tees up deals to start flowing in. But we can but wait.
FeverTree, understand your caution. But with ovarian/prostate study’s due and hopefully new deals on the horizon you could well see your previous paper losses recouped.
A Great RNS here and one that tees up ANGLE to make 2024 rather spectacular.
As a “shareholder” you must be delighted FeverTreeMan?
And Bantham, TwoGoodToDie et al you must be very pleased that AGL’s service offering is one that will benefit the advancement of cancer treatment worldwide?
“ Announcing new contract with large pharma company, Eisai Inc. A pilot study using ANGLE’s Portrait HER2 test will assess Eisai’s novel therapeutic for breast cancer, BB-1701. This opportunity could open doors for future large-scale opportunities with Eisai Inc.”
https://x.com/parsortix/status/1742574173837234262?s=46&t=IHEn1TE0c7FNFBktt6H8XQ
#AGL are attending the Proactive One2One Investor Forum specialising in the biomedical/pharmaceutical sectors on 11th January 2024
One would like to think they might have some updates in store prior (contract wins or 3rd party molecular results perhaps?)
@proactive_UK @Parsortix
Hi Bantham,
In your previous posts you've seemed quite open minded and balanced. But this post seems a little one sided don’t you think?
Pre Xmas critics were hammering Newland for not delivering deals. Now he delivers a deal, albeit a pilot study that if successful could lead to further business with this client. A client who is both a “large” and “global” pharmaceutical company. (Check the about/history section of their website).
Then to credit TwoGood with loving how he sums this news up… An obvious moron/troll with nothing to add but snide one-liners. Again seems a little one sided.
Let’s see how this (and hopefully other deals) progress shall we?
Happy New Year FeverTree
I thought as an existing holder, you’d be a bit happier about today’s news.
In November’s presentation, the CEO describes this very dynamic of pilot/preliminary studies ending up leading to much bigger deals with the pharmaceutical companies in question.
As you’ve stated in the past, deals with big pharmaceutical companies are complicated things and any enterprise worth it’s salt would want to trial the product before doing a bigger all encompassing deal.
As a longterm holder yourself it might be prudent to see how the pilot study goes before slating the company in which you’ve invested. (Better chance of seeing a return on your position that way surely?)
Also the key takeaway from the RNS is that it’s a $250,000 PILOT study and…
“Success in the pilot study offers the potential for multiple large scale follow-up studies.”